Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.

Annals of hematology - 1 Apr 2024

Streuer Alexander, Jann Johann-Christoph, Boch Tobias, Mossner Maximilian, Riabov Vladimir, Schmitt Nanni, Altrock Eva, Xu Qingyu, Demmerle Marie, Nowak Verena, Oblaender Julia, Palme Iris, Weimer Nadine, Rapp Felicitas, Metzgeroth Georgia, Hecht Anna, Höger Thomas, Merz Christian, Hofmann Wolf-Karsten, Nolte Florian, Nowak Daniel

Abstract excerpt

In low-risk Myelodysplastic Neoplasms (MDS), increased activity of apoptosis-promoting factors such as tumor necrosis factor (TNFα) and pro-apoptotic Fas ligand (CD95L) have been described as possible pathomechanisms leading to impaired erythropoiesis. Asunercept (APG101) is a novel therapeutic fusion protein blocking CD95, which has previously shown partial efficacy in reducing transfusion requirement in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Bone Marrow

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clone Cells

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38413410
DOI: 10.1007/s00277-024-05664-5
PMCID: PMC10940491

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.PMID 38413410Read ↗

Response Predictors and Clonal Evolution during Thalidomide Therapy in Myelodysplastic Neoplasms with Increased BlastsSemantic proximity Read ↗

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasmsSemantic proximity Read ↗

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.Semantic proximity Read ↗

Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.Semantic proximity Read ↗

Myelodysplastic syndrome is not merely “preleukemia”Semantic proximity Read ↗

Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms.Semantic proximity Read ↗

Long-Term Clinical and Molecular Dynamics in Hypoplastic Myelodysplastic Neoplasia Treated With Immunosuppressive Therapy.Semantic proximity Read ↗

Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy.Semantic proximity Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read ↗

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapySemantic proximity Read ↗

SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.